What is market sentiment?

Market sentiment is the overall attitude of investors toward a particular security or the financial market as a whole. It reflects whether investors are feeling bullish (optimistic) or bearish (pessimistic) based on price action, news flow, economic indicators, and collective psychology. Kinvestor tracks real-time market sentiment across major indices and individual equities.

How does financial news affect stock prices?

Financial news affects stock prices by shifting investor sentiment. Positive earnings reports, strong economic data, or favorable Fed decisions typically boost stock prices, while negative news can trigger sell-offs. The speed and magnitude of price moves depends on whether the news beats or misses market expectations.

What are stock market movers?

Stock market movers are stocks with significant price changes — either up (gainers) or down (losers) — within a trading session. Movers are typically driven by earnings reports, analyst upgrades or downgrades, macroeconomic news, or major corporate announcements. Kinvestor tracks the biggest movers in real time across the S&P 500, NASDAQ, and Dow Jones.

What is earnings season?

Earnings season is the period each quarter when publicly traded companies report their financial results. It occurs four times per year: January–February (Q4 results), April–May (Q1 results), July–August (Q2 results), and October–November (Q3 results). During earnings season, stocks often experience heightened volatility as results beat or miss analyst expectations.

What is financial intelligence?

Financial intelligence is the ability to understand and interpret financial data, market trends, news, and sentiment to make informed investment decisions. It combines real-time market data, news aggregation, sentiment analysis, and economic indicators into actionable insight. Kinvestor is a financial intelligence platform that aggregates these signals in one place.

Financial Intelligence

Featured Headlines

ROSEN, LEADING TRIAL ATTORNEYS, Encourages AST SpaceMobile, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ASTS

1 / 5◆ Neutral

GlobeNewswire Inc.·1h ago

ROSEN, LEADING TRIAL ATTORNEYS, Encourages AST SpaceMobile, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ASTS

Rosen Law Firm is reminding investors who purchased AST SpaceMobile securities between March 4, 2025 and July 15, 2026 of an important November 13, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made false statements regarding the company's capital requirements, liquidity position, competitive standing in the satellite D2C market, and user adoption rates, resulting in material misstatements that caused investor damages.

ASTS

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

GlobeNewswire Inc.·1h ago

◆ Neutral

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

HUTCHMED has completed an exclusive development and license agreement with GSK subsidiary, granting GSK worldwide rights…

HCMGSK

Better Consumer Stock for 2026: Airbnb vs. DICK'S Sporting Goods

The Motley Fool·1h ago

◆ Neutral

Better Consumer Stock for 2026: Airbnb vs. DICK'S Sporting Goods

The article compares Airbnb and DICK'S Sporting Goods as investment options for 2026. Airbnb boasts a high 20.4% net mar…

ABNBDKSNKEBKNG

Can Micron Stock Keep Climbing After a 10-Fold Run? Here's What Its Past Booms Say.

The Motley Fool·1h ago

◆ Neutral

Can Micron Stock Keep Climbing After a 10-Fold Run? Here's What Its Past Booms Say.

Micron Technology stock has surged 10-fold from its 2024 closing price, jumping 239% in 2025 and tripling in 2026 to aro…

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

GlobeNewswire Inc.·1h ago

◆ Neutral

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Ascentage Pharma announced that its novel Bcl-2 inhibitor lisaftoclax (APG-2575) has received Breakthrough Therapy Desig…

AAPG